Aurobindo Pharma Ltd Q4 consolidated PAT climbs to Rs. 998.57 crore

AUROBINDO PHARMA LTD. has reported financial results for the period ended March 31, 2020.

Financial Results (Q4 FY19-20) - QoQ Comparison

The company has reported total income of Rs.6191.02 crores during the period ended March 31, 2020 as compared to Rs.5925.93 crores during the period ended December 31, 2019.

The company has posted net profit / (loss) of Rs.998.57 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.816.67 crores for the period ended December 31, 2019.

The company has reported EPS of Rs.14.50 for the period ended March 31, 2020 as compared to Rs.12.04 for the period ended December 31, 2019.

Financials	Q4 FY19-20	Q3 FY19-20	% Change
Total Income	₹ 6191.02 crs	₹ 5925.93 crs	4.47%
Net Profit	₹ 998.57 crs	₹ 816.67 crs	22.27%
EPS	₹ 14.50	₹ 12.04	20.43%

Financial Results (Q4 FY19-20) - YoY Comparison

The company has reported total income of Rs.6191.02 crores during the period ended March 31, 2020 as compared to Rs.5324.47 crores during the period ended March 31, 2019.

The company has posted net profit / (loss) of Rs.998.57 crores for the period ended March 31, 2020 as against net profit / (loss) of Rs.528.36 crores for the period ended March 31, 2019.

The company has reported EPS of Rs.14.50 for the period ended March 31, 2020 as compared to Rs.9.99 for the period ended March 31, 2019.

Financials	Q4 FY19-20	Q4 FY18-19	% Change
Total Income	₹ 6191.02 crs	₹ 5324.47 crs	16.27%
Net Profit	₹ 998.57 crs	₹ 528.36 crs	88.99%
EPS	₹ 14.50	₹ 9.99	45.15%

Financial Results (12 months ended FY 19-20) - YoY Comparison

The company has reported total income of Rs.23184.70 crores during the 12 months period ended March 31, 2020 as compared to Rs.19679.21 crores during the 12 months period ended March 31, 2019.

The company has posted net profit / (loss) of Rs.3118.09 crores for the 12 months period ended March 31, 2020 as against net profit / (loss) of Rs.2360.53 crores for the 12 months period ended March 31, 2019.

The company has reported EPS of Rs.48.32 for the 12 months period ended March 31, 2020 as compared to Rs.40.36 for the 12 months period ended March 31, 2019.

Financials	Year Ended FY19-20	Year Ended FY18-19	% Change
Total Income	₹ 23184.70 crs	₹ 19679.21 crs	17.81%
Net Profit	₹ 3118.09 crs	₹ 2360.53 crs	32.09%
EPS	₹ 48.32	₹40.36	19.72%

Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said: "The new fiscal year has begun with lot of challenges that the globe and industry had never witnessed. We are committed in protecting the health and wellbeing of our employees, their families and other stakeholders. We are proud of our employees and other stakeholders for their commitment during the crisis for ensuring the business continuity.

We have closed FY20 with a healthy performance in Q4. The growth was seen across all our geographies. Diversified product basket has helped us to maintain the growth momentum in our core geographies like USA and Europe. We remain focused on strengthening our existing businesses, developing a differentiated & specialty product basket and regulatory compliance."

Shares of AUROBINDO PHARMA LTD. was last trading in BSE at Rs.750.65 as compared to the previous close of Rs. 733.9. The total number of shares traded during the day was 194503 in over 4626 trades.

The stock hit an intraday high of Rs. 758.65 and intraday low of 736. The net turnover during the day was Rs. 145552293.

Source : Equity Bulls

Keywords